"Unreasonable" foreign pharma investment prompts Indian call for policy review
This article was originally published in Scrip
The debate on the need to review foreign direct investment (FDI) norms in the Indian pharmaceutical sector is set to reach a new crescendo, with domestic firms building their case against a freer regime with data suggesting that foreign companies have not made substantial investments in fixed assets or R&D in the country over a 15-year period.
You may also be interested in...
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.